Xenon Pharmaceuticals Inc. (XENE): Ian Mortimer , CFO of Xenon Pharmaceuticals Inc. purchased 5,300 shares on Jun 24, 2016. The Insider buying transaction was reported by the company on Jun 28, 2016 to the Securities and Exchange Commission. The shares were purchased at $6.20 per share for a total value of $32,940.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 24, 2015, Y. Paul Goldberg (VP of Clinical Development) sold 22,149 shares at $8.98 per share price.
Shares of Xenon Pharmaceuticals Inc (XENE) ended Monday, Jun 27, 2016 session in red amid volatile trading. The shares closed down -0.3 points or -4.76% at $6 with 27,038 shares getting traded. Post opening the session at $6.3, the shares hit an intraday low of $5.76 and an intraday high of $6.3 and the price vacillated in this range throughout the day. The company has a market cap of $86 M and the number of outstanding shares has been calculated to be 1,44,03,866 shares. The 52-week high of Xenon Pharmaceuticals Inc is $12.2145 and the 52-week low is $5.6501.
Company has been under the radar of several Street Analysts.Xenon Pharmaceuticals Inc is Reiterated by Jefferies to Buy and the brokerage firm has raised the Price Target to $ 13 from a previous price target of $10 .The Rating was issued on Apr 14, 2016.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company has built a core platform Extreme Genetics enabling the discovery of validated drug targets by studying rare human diseases with extreme traits including diseases caused by mutations in ion channels known as channelopathies. Its product pipeline includes Glybera which is a gene therapy approved in the EU for the treatment of patients with the orphan lipid disorder LPLD; TV-45070 which is a small-molecule inhibitor of the sodium channel Nav1.7; GDC-0276 which is a selective oral Nav1.7 small-molecule inhibitor being developed for the treatment of pain and XEN801 which is a selective small molecule inhibitor of SCD1 being developed for the treatment of dermatological disorders. FDA has granted fast track designations to TV-45070 for EM and to Glybera for LPLD and received orphan drug designation.